Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) protein of the Influenza B virus Yamagata lineage is a major surface glycoprotein essential for viral entry into host cells. It mediates attachment to sialic acid receptors and subsequent membrane fusion. As a key immunogen, it is a crucial component of influenza vaccines, particularly quadrivalent formulations targeting both Yamagata and Victoria lineages. Antigenic variations within HA necessitate continuous surveillance and vaccine updates.
Binding to sialic acid receptors on host cells, triggering receptor-mediated endocytosis, followed by pH-dependent conformational change and membrane fusion. Vaccines elicit neutralizing antibodies that block HA's function.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin protein of Influenza B virus Yamagata lineage (HA (Yamagata lineage)).